+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients

International Journal of Cancer 136(9): 2158-2165

Circulating tumor DNA (ctDNA) is a new circulating tumor biomarker which might be used as a prognostic biomarker in a way similar to circulating tumor cells (CTCs). Here, we used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compare ctDNA and CTC detection rates and prognostic value in metastatic TNBC patients. Forty patients were enrolled before starting a new line of treatment. TP53 mutations were characterized in archived tumor tissues and in plasma DNA using two next generation sequencing (NGS) platforms in parallel. Archived tumor tissue was sequenced successfully for 31/40 patients. TP53 mutations were found in 26/31 (84%) of tumor samples. The same mutation was detected in the matched plasma of 21/26 (81%) patients with an additional mutation found only in the plasma for one patient. Mutated allele fractions ranged from 2 to 70% (median 5%). The observed correlation between the two NGS approaches (R(2) = 0.903) suggested that ctDNA levels data were quantitative. Among the 27 patients with TP53 mutations, CTC count was ≥1 in 19 patients (70%) and ≥5 in 14 patients (52%). ctDNA levels had no prognostic impact on time to progression (TTP) or overall survival (OS), whereas CTC numbers were correlated with OS (p = 0.04) and marginally with TTP (p = 0.06). Performance status and elevated LDH also had significant prognostic impact. Here, absence of prognostic impact of baseline ctDNA level suggests that mechanisms of ctDNA release in metastatic TNBC may involve, beyond tumor burden, biological features that do not dramatically affect patient outcome.

(PDF emailed within 0-6 h: $19.90)

Accession: 052091526

Download citation: RISBibTeXText

PMID: 25307450

DOI: 10.1002/ijc.29265

Related references

Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Research and Treatment 147(2): 325-333, 2015

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research 21(12): 2771-2779, 2016

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Research 16(5): 445, 2015

Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology 36(6): 523-524, 2018

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. Oncotarget 8(3): 5309-5322, 2016

Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Annals of Oncology 24(11): 2766-2772, 2014

Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy. Bulletin of Experimental Biology and Medicine 157(1): 159-161, 2015

Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clinical Cancer Research 23(1): 88-96, 2016

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia 18(11): 647-653, 2016

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncologica 50(5): 700-710, 2011

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Annals of Oncology 21(9): 1765-1771, 2010

A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol. Jmir Research Protocols 5(3): E167, 2016

Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chinese Journal of Cancer Research 30(3): 315-326, 2018

Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Cell Biochemistry and Biophysics 65(2): 263-273, 2013

Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer. Annals of Surgical Oncology 22 Suppl 3: S552-S558, 2016